PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction

Sponsor
King's College London
Study ID
NCT07533747
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Coronary Microvascular Dysfunction (CMD)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Some people experience chest pain and shortness of breath, but when they have tests, no blockages are found in their main heart arteries. The most common cause of symptoms is related to abnormalities in the small blood vessels, also known as 'small vessel angina' or Coronary Microvascular Dysfunction (CMD). Currently, the diagnosis of CMD requires additional measurements of blood flow in the heart vessel during a minimally invasive procedure known as a coronary angiogram. CMD affects many people and can lead to repeated hospital visits and a lower quality of life, and diagnosing the condition leads to better patient outcomes. However, there are still no widely available, proven treatments for this condition and therefore several patients remain symptomatic. This study aims to find better ways to treat CMD, especially by understanding how the heart uses energy and how this might relate to symptoms.

Key Dates

Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
May 31, 2031
Completion
May 31, 2031

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin Therapy Arm
    Empagliflozin 10mg OD

Primary Outcome Measure

Myocardial Perfusion Reserve [ Time Frame: 8 weeks ]

Central Contacts

Related Studies